Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

DeSimone RA, Plimier C, Lee C, Kanias T, Cushing MM, Sachais BS, et al. Additive effects of blood donor smoking and gamma irradiation on outcome measures of red blood cell transfusion. Transfusion. 2020;60(6):1175-1182.

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, et al. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Sci Rep. 2020;10(1):13094.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, et al. Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Mod Pathol. 2020;33(2):319.

Saqi A, Mukhopadhyay S, Butt Y, Doxtader E, Heymann JJ, Larsen BT, et al. E-cigarette or vaping product use-associated lung injury: What is the role of cytologic assessment? Cancer Cytopathol. 2020;128(6):371-380.

Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ. 2020;27(5):1455-1456.

Bagheri S, Pantrangi M, Sodhi SK, Bagheri S, Oellers P, Scholl HP. A NOVEL LARGE HOMOZYGOUS DELETION IN THE CELLULAR RETINALDEHYDE-BINDING PROTEIN GENE (RLBP1) IN A PATIENT WITH RETINITIS PUNCTATA ALBESCENS. Retin Cases Brief Rep. 2020;14(1):85-89.

Chiang GC, Pisapia DJ, Liechty B, Magge R, Ramakrishna R, Knisely J, et al. The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas. J Neuroimaging. 2020;30(6):901-909.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.

Laurence J, J Mulvey J, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020;95(12):1553-1561.